These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 10221467

  • 1. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.
    Ling LH, Ahlskog JE, Munger TM, Limper AH, Oh JK.
    Mayo Clin Proc; 1999 Apr; 74(4):371-5. PubMed ID: 10221467
    [Abstract] [Full Text] [Related]

  • 2. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.
    Townsend M, MacIver DH.
    Heart; 2004 Aug; 90(8):e47. PubMed ID: 15253989
    [Abstract] [Full Text] [Related]

  • 3. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A, Poewe W.
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pleuropulmonary disease associated with dopamine agonist therapy.
    Bhatt MH, Keenan SP, Fleetham JA, Calne DB.
    Ann Neurol; 1991 Oct; 30(4):613-6. PubMed ID: 1686385
    [Abstract] [Full Text] [Related]

  • 6. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    Clin Neuropharmacol; 2008 Oct; 31(1):19-24. PubMed ID: 18303487
    [Abstract] [Full Text] [Related]

  • 7. A case of constrictive pericarditis during cabergoline treatment for hyperprolactinaemia.
    Löndahl M, Nilsson A, Lindgren H, Katzman P.
    Eur J Endocrinol; 2008 Apr; 158(4):583-5. PubMed ID: 18362307
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Use of the dopamine agonist cabergoline in the treatment of movement disorders.
    Marco AD, Appiah-Kubi LS, Chaudhuri KR.
    Expert Opin Pharmacother; 2002 Oct; 3(10):1481-7. PubMed ID: 12387694
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
    Frans E, Dom R, Demedts M.
    Eur Respir J; 1992 Feb; 5(2):263-5. PubMed ID: 1348483
    [Abstract] [Full Text] [Related]

  • 12. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
    Andersohn F, Garbe E.
    Mov Disord; 2009 Jan 15; 24(1):129-33. PubMed ID: 19170199
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
    Pullan PT.
    Intern Med J; 2009 Apr 15; 39(4):213-5. PubMed ID: 19402858
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis.
    Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B.
    Clin Neuropharmacol; 2006 Apr 15; 29(2):80-6. PubMed ID: 16614540
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
    Trifirò G, Morgante L, Tari M, Arcoraci V, Savica R.
    J Am Geriatr Soc; 2008 Feb 15; 56(2):371-3. PubMed ID: 18251828
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.